Naumann RW, et al. - Investigators identified 12 potentially practice-changing, randomized phase III trials in front line ovarian cancer. They added biologic therapy to primary chemotherapy and/or used it in the maintenance setting. They included PARP inhibitors (PARPi), anti-angiogenic agents, immuno-oncology agents, and combinations of these agents in the trials. They later reported one trial, one terminated for futility whereas 10 were ongoing. The utility of maintenance targeted therapy was focussed in all the trials. They also recognized 7 randomized phase III trials employing hyperthermic intraperitoneal chemotherapy (HIPEC) additionally in the setting of upfront ovarian cancer treatment.